Figure 26, Network for Total Control: Highly Emetogenic Chemotherapy and Anthracycline/Cyclophosphamide — Acute Phase - Clinical Review Report: Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo)

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo): (Purdue Pharma): Indication: In combination with dexamethasone, once-per-cycle treatment for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, or with moderately emetogenic cancer chemotherapy that is uncontrolled by a 5-hydroxytryptamine-3 receptor antagonist alone [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jun.

Cover of Clinical Review Report: Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo)

Clinical Review Report: Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo): (Purdue Pharma): Indication: In combination with dexamethasone, once-per-cycle treatment for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, or with moderately emetogenic cancer chemotherapy that is uncontrolled by a 5-hydroxytryptamine-3 receptor antagonist alone [Internet].

Show details

Contents

Figure 26Network for Total Control: Highly Emetogenic Chemotherapy and Anthracycline/Cyclophosphamide — Acute Phase

APR = aprepitant; DEX = dexamethasone; FOS = fosaprepitant; GRA = granisetron; NET = netupitant; OND = ondansetron; PAL = palonosetron.

Source: NEPA MTC report.⁴⁵

From: Appendix 6, Summary of Mixed-Treatment Comparisons

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Contents

Views

Cite this Page
Clinical Review Report: Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo): (Purdue Pharma): Indication: In combination with dexamethasone, once-per-cycle treatment for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, or with moderately emetogenic cancer chemotherapy that is uncontrolled by a 5-hydroxytryptamine-3 receptor antagonist alone [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jun. Figure 26, Network for Total Control: Highly Emetogenic Chemotherapy and Anthracycline/Cyclophosphamide — Acute Phase.
PDF version of this title (4.3M)

Other titles in this collection

CADTH Common Drug Reviews

Recent Activity

Clear Turn Off Turn On

Figure 26, Network for Total Control: Highly Emetogenic Chemotherapy and Anthrac...
Figure 26, Network for Total Control: Highly Emetogenic Chemotherapy and Anthracycline/Cyclophosphamide — Acute Phase - Clinical Review Report: Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo)

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on